Recently, TIE2 has emerged as a popular target for therapeutic intervention in PCG as TIE2 activation, and the use of small-molecule inhibitors of negative TIE2 regulation have shown beneficial effects of improved SC morphology, increased outflow facility, and reduction of IOP in animal models of glaucoma (28, 29). Here, TEK is linked to glaucoma.